In 23% to 50% of intrahepatic cholangiocarcinoma and 30% to 40% of extrahepatic cholangiocarcinoma, the KRAS gene often has mutations, which accelerate tumor progression (73, 74). This evidence concerns the gene KRAS and neoplasm.